LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breakthrough Report for Microbiology Lab Results a Game-Changer for Infectious Disease Treatment

By LabMedica International staff writers
Posted on 28 Aug 2023
Print article
Image: The OneChoice report for microbiology lab results empowers clinicians to provide optimal care (Photo courtesy of Arkstone)
Image: The OneChoice report for microbiology lab results empowers clinicians to provide optimal care (Photo courtesy of Arkstone)

Infectious pathogens continually evolve, becoming stronger and more strategic as they adapt to new environments and develop resistance to existing treatments. Despite this ongoing evolution, the essential technologies in the fight against antimicrobial resistance (AMR) often lag behind. While pathogens advance, clinical tools can become outdated, failing to provide physicians with accurate and timely information. For example, obsolete lab reporting technologies not only lack efficiency but also hamper the battle against AMR. Now, a cutting-edge decision-supporting clinical tool is bridging this gap by utilizing modern technologies for precise, rapid, and effective patient care in the digital age.

Arkstone Medical Solutions (Boca Raton, FL, USA) has introduced a groundbreaking advancement—the OneChoice report for microbiology lab results. Building on the success of its molecular lab results OneChoice report, which has benefited countless patients and earned the trust of numerous healthcare providers, Arkstone has extended its revolutionary technology to the realm of microbiology. The OneChoice report represents a transformative step in infectious disease treatment. Unlike traditional microbiology lab reports that present raw text data for interpretation, Arkstone's OneChoice decision engine analyzes a range of factors to provide precision-guided treatment recommendations. By harnessing advanced artificial intelligence and a deep understanding of infectious diseases, Arkstone empowers healthcare providers with personalized medicine tailored to each patient's specific requirements.

At the heart of the OneChoice report is the PathFinder system, which identifies potentially pathogenic organisms within samples, laying the foundation for more accurate treatment decisions. This innovative tool considers various sensitivities tested in the lab and evaluates their relevance based on the source of the sample. Additionally, the report features the MedsMatrix, a visual table that highlights effective drugs alongside considerations like allergies or pregnancy status. The report also offers OneChoice Plus—an interactive online version accessed through a QR code on each report. OneChoice Plus equips clinicians with a comprehensive toolkit for efficient patient care management. It provides tools for dosage adjustments, drug references, drug interaction checks, GFR, and CrCL calculators—all at the fingertips of physicians. Furthermore, OneChoice Plus offers translations in multiple languages, facilitating clear communication and comprehension for healthcare providers and patients across the world.

"We are thrilled to introduce these groundbreaking advancements to our OneChoice report," says Dr. Ari Frenkel, infectious disease specialist, and Co-Founder & Chief Science Officer of Arkstone. "Precision-guided medicine is the future of infectious disease treatment, and our latest innovations will empower clinicians to provide optimal care while upholding antimicrobial stewardship principles."

"With the launch of the OneChoice report for microbiology lab results, Arkstone is poised to make an even greater impact on the healthcare landscape," said Dave Gross, Co-Founder & CTO of Arkstone. "Our commitment to evidence-based information and continuous innovation has positioned us as the trusted partner for healthcare providers worldwide. By expanding our technology to microbiology, we're enabling healthcare providers to make more informed decisions and ultimately improve patient outcomes."

Related Links:
Arkstone Medical Solutions 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.